Ultragenyx Pharmaceu (RARE)

$29.70 +0.01 (0.03%)
Market Cap 2.86B
Revenue (ttm) 560.23M
Net Income (ttm) -569.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -101.60%
Debt to Equity Ratio 0.00
Volume 1,699,440
Avg Vol 2,117,066
Day's Range N/A - N/A
Shares Out 96.37M
Stochastic %K 89%
Beta 0.25
Analysts Strong Sell
Price Target $85.85

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
Bio_Invest101
Bio_Invest101 Aug. 16 at 1:09 PM
$ARWR VP is a changed man, to some degree ? $RARE
0 · Reply
commanche
commanche Aug. 14 at 8:38 AM
$RARE lets get back to 30 today
1 · Reply
justiceforb_85
justiceforb_85 Aug. 14 at 3:51 AM
$RARE why is this doing so poorly? They have an anticipated BLA submission later this year and are currently generating revenue (I know, not profitable yet, but as are most biotechs).
0 · Reply
LQQKER_INSIDER
LQQKER_INSIDER Aug. 13 at 8:52 PM
$RARE MOON🌙 IT !!!
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 13 at 3:44 PM
$XBI $SRPT $TARS $RARE Finally time for some love for biotech. Rotate!
0 · Reply
LDT79
LDT79 Aug. 12 at 3:57 PM
$RARE ....and the shorting continues
0 · Reply
KWalzz
KWalzz Aug. 10 at 9:58 AM
$RARE sitting now at average 27.5 with 20k shares and I say this is a hidden gem in bio world which will shine sooner or later.
1 · Reply
AlexTeddy2025
AlexTeddy2025 Aug. 10 at 3:30 AM
$RARE
0 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 10:00 PM
Canaccord Genuity has updated their rating for Ultragenyx Pharmaceutical ( $RARE ) to Buy with a price target of 128.
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 5:04 PM
$RARE narrows Q2 loss but stock struggles — what's holding it back? 🤔 Ultragenyx's Q2 loss of $1.17 per share beat estimates, and revenue climbed 13% year over year, driven by strong product sales. Yet, shares are down 31.3% YTD as pipeline setbacks and rising expenses weigh on momentum. Full analysis here 👉 https://www.zacks.com/stock/news/2673751/ultragenyxs-q2-loss-narrower-than-expected-revenues-rise-yy?cid=sm-stocktwits-2-2673751-body-6418&ADID=SYND_STOCKTWITS_TWEET_2_2673751_BODY_6418
0 · Reply
Latest News on RARE
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Aug 18, 2025, 8:00 AM EDT - 10 hours ago

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 12:42 AM EDT - 12 days ago

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 5, 2025, 4:01 PM EDT - 13 days ago

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Jul 30, 2025, 8:30 AM EDT - 19 days ago

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst

Jul 29, 2025, 9:10 AM EDT - 20 days ago

Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

Jul 28, 2025, 1:16 PM EDT - 21 days ago

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 18, 2025, 4:30 PM EDT - 4 weeks ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

Jul 18, 2025, 3:07 PM EDT - 4 weeks ago

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 14, 2025, 8:14 AM EDT - 5 weeks ago

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

AAPL

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder

Jul 11, 2025, 4:45 PM EDT - 5 weeks ago

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Jul 11, 2025, 4:30 PM EDT - 5 weeks ago

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Jul 10, 2025, 10:06 AM EDT - 5 weeks ago

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Jul 10, 2025, 8:00 AM EDT - 5 weeks ago

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MEI

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Jul 9, 2025, 4:05 PM EDT - 5 weeks ago

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Jun 27, 2025, 8:00 AM EDT - 7 weeks ago

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 5:00 PM EDT - 2 months ago

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

May 14, 2025, 4:30 PM EDT - 3 months ago

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

May 7, 2025, 5:00 PM EDT - 3 months ago

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:31 PM EDT - 3 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

May 6, 2025, 4:01 PM EDT - 3 months ago

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Apr 30, 2025, 5:00 PM EDT - 3 months ago

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Apr 16, 2025, 9:49 AM EDT - 4 months ago

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Ultragenyx to Participate at Investor Conferences in March

Feb 24, 2025, 4:30 PM EST - 6 months ago

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 9:53 PM EST - 6 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Feb 13, 2025, 4:01 PM EST - 6 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

Feb 6, 2025, 4:30 PM EST - 6 months ago

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

Feb 5, 2025, 8:00 AM EST - 6 months ago

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

Jan 15, 2025, 2:05 PM EST - 7 months ago

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Jan 12, 2025, 11:00 AM EST - 7 months ago

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:30 PM EST - 8 months ago

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

Jan 6, 2025, 2:00 AM EST - 8 months ago

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Dec 20, 2024, 3:00 AM EST - 8 months ago

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

Dec 19, 2024, 4:05 PM EST - 8 months ago

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

Ultragenyx to Participate in Investor Conferences in December

Nov 26, 2024, 4:30 PM EST - 9 months ago

Ultragenyx to Participate in Investor Conferences in December

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 12, 2024, 11:12 AM EST - 9 months ago

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit

Nov 9, 2024, 10:30 AM EST - 10 months ago

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 10:40 PM EST - 10 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

Nov 5, 2024, 4:01 PM EST - 10 months ago

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Oct 3, 2024, 4:30 PM EDT - 11 months ago

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

Sep 26, 2024, 8:00 AM EDT - 11 months ago

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

Ultragenyx to Participate in Investor Conferences in September

Aug 29, 2024, 4:30 PM EDT - 1 year ago

Ultragenyx to Participate in Investor Conferences in September

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Aug 22, 2024, 10:22 AM EDT - 1 year ago

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 6:07 PM EDT - 1 year ago

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript

Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LP

Aug 2, 2024, 8:15 AM EDT - 1 year ago

Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LP

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

Jul 22, 2024, 1:04 PM EDT - 1 year ago

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

IONS

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2024, 8:49 PM EDT - 1 year ago

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 12, 2024, 4:05 PM EDT - 1 year ago

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Bio_Invest101
Bio_Invest101 Aug. 16 at 1:09 PM
$ARWR VP is a changed man, to some degree ? $RARE
0 · Reply
commanche
commanche Aug. 14 at 8:38 AM
$RARE lets get back to 30 today
1 · Reply
justiceforb_85
justiceforb_85 Aug. 14 at 3:51 AM
$RARE why is this doing so poorly? They have an anticipated BLA submission later this year and are currently generating revenue (I know, not profitable yet, but as are most biotechs).
0 · Reply
LQQKER_INSIDER
LQQKER_INSIDER Aug. 13 at 8:52 PM
$RARE MOON🌙 IT !!!
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 13 at 3:44 PM
$XBI $SRPT $TARS $RARE Finally time for some love for biotech. Rotate!
0 · Reply
LDT79
LDT79 Aug. 12 at 3:57 PM
$RARE ....and the shorting continues
0 · Reply
KWalzz
KWalzz Aug. 10 at 9:58 AM
$RARE sitting now at average 27.5 with 20k shares and I say this is a hidden gem in bio world which will shine sooner or later.
1 · Reply
AlexTeddy2025
AlexTeddy2025 Aug. 10 at 3:30 AM
$RARE
0 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 10:00 PM
Canaccord Genuity has updated their rating for Ultragenyx Pharmaceutical ( $RARE ) to Buy with a price target of 128.
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 5:04 PM
$RARE narrows Q2 loss but stock struggles — what's holding it back? 🤔 Ultragenyx's Q2 loss of $1.17 per share beat estimates, and revenue climbed 13% year over year, driven by strong product sales. Yet, shares are down 31.3% YTD as pipeline setbacks and rising expenses weigh on momentum. Full analysis here 👉 https://www.zacks.com/stock/news/2673751/ultragenyxs-q2-loss-narrower-than-expected-revenues-rise-yy?cid=sm-stocktwits-2-2673751-body-6418&ADID=SYND_STOCKTWITS_TWEET_2_2673751_BODY_6418
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Aug. 6 at 5:02 PM
$RARE just read the morgan stanley report things are headed in the right direction MS even raised some of the estimates going fwd Even said $RARE would be profitable for 2027, but I don't believe they'll be an independent entity then too much value here added today
0 · Reply
NYG4ever
NYG4ever Aug. 6 at 4:50 PM
$RARE added...surprised it took a hit today, but broader bio complex is beaten down
0 · Reply
JohnGod
JohnGod Aug. 6 at 4:04 PM
$RARE added also
0 · Reply
Westieofwallst
Westieofwallst Aug. 6 at 3:37 PM
$RARE added here
0 · Reply
SteadyTrade55
SteadyTrade55 Aug. 6 at 3:34 PM
$RARE super strong support at $26.60 - including a 108k block trade just a few minutes ago.
0 · Reply
alexpitti
alexpitti Aug. 6 at 3:19 PM
I feel like $LRMR and $RARE have a better chance of good data than $ATYR. I'm concerned that ATYR has very little support for this drug given the lack of data. Maybe $RARE has a 50% chance of good data $LRMR a 35% chance of good data $ATYR only a 5% chance
8 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 3:19 PM
$RARE just surprised to the upside — here’s why it matters Q2 loss came in narrower than expected, with 13% revenue growth driven by rising demand across all four rare disease drugs. Full breakdown here 👉 https://www.zacks.com/stock/news/2673751/ultragenyxs-q2-loss-narrower-than-expected-revenues-rise-yy?cid=sm-stocktwits-2-2673751-teaser-6336&ADID=SYND_STOCKTWITS_TWEET_2_2673751_TEASER_6336
0 · Reply
SteadyTrade55
SteadyTrade55 Aug. 6 at 3:11 PM
$RARE crazy gift
0 · Reply
alexpitti
alexpitti Aug. 6 at 2:55 PM
$RARE looks like a cheap stock
0 · Reply
alexpitti
alexpitti Aug. 6 at 2:54 PM
$RARE brutal day. stock is now at an all time low
0 · Reply
JarvisFlow
JarvisFlow Aug. 6 at 2:18 PM
Cantor Fitzgerald updates rating for Ultragenyx Pharmaceutical ( $RARE ) to Overweight, target set at 112 → 105.
0 · Reply
CUBAN_CIGAR
CUBAN_CIGAR Aug. 6 at 1:55 PM
$RARE ***COVERED MY SHORTS and went long here, EARNINGS WERE ACTUALLY ok, stock beat up, lets see $31+ today!***
0 · Reply